USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
08 Mar 2023 | 03:45 PM GMT

Sprint: Beyond Piloting: Growth and Scaling of Pharma-DTx Partnerships (Part 1)

Anchored by:

Mirza Ahmed
Partner
BRIDGE-ME

Participants:

Mirza Ahmed PartnerBridge-ME
Mirza Ahmed
PartnerBridge-ME
Ashutosh Malhotra Director Digital Health Strategy & PartnersDaiichi Sankyo
Ashutosh Malhotra
Director Digital Health Strategy & PartnersDaiichi Sankyo
Carman Ho Vice PresidentL1 Health
Carman Ho
Vice PresidentL1 Health
Ivan Jurisic Head of ProductPatients Influence
Ivan Jurisic
Head of ProductPatients Influence
Jock Thompson CEOHyduro, Inc.
Jock Thompson
CEOHyduro, Inc.
Kevin Darcy Director, Link StrategyVeeva
Kevin Darcy
Director, Link StrategyVeeva
Malin Johansson Vice PresidentNovo Nordisk
Malin Johansson
Vice PresidentNovo Nordisk
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected Health
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Patrick Leyseele Founder3.life
Patrick Leyseele
Founder3.life
Ralph Morales III Managing DirectorShokunin Ventures
Ralph Morales III
Managing DirectorShokunin Ventures
Tahir Hussain Global Pharma Business Dev. Digital HealthBiofourmis
Tahir Hussain
Global Pharma Business Dev. Digital HealthBiofourmis

About this Meeting

Outcome focused, 2 part meetings - walk away with insights. 

 

Participate in a Digital Health Sprint in order to: 

 

  • Deep dive into a topic over 2 focused sessions. 

  • Engage with a small group of 10 global thought-leaders throughout.  

  • This sprint is outcome-focused: HealthXL and participants create exclusive outputs.  

  • Grow your network with our break out sessions.


Pharma-DTx Partnerships can be a good strategy when they speak the same language. We have seen some successful pilots, but there are some challenges when it comes to figuring out how best to spread and sustain innovations that deliver value at scale with a relevant ROI for the pharma company. What are the main obstacles to the growth and scalability of DTx-Pharma partnerships? What would successful growth and scaling look like and how do we get there? 

In this sprint, we will break this down into 5 key challenges and agree on 5 key recommendations to overcome them. At the end of the session, HealthXL will put together an output with the learnings from the group. Some of the major challenges we may tackle (these are some examples - the group will agree on the problems they want to address):   

  • Customer acquisition cost (CAC) and retention: CAC is usually very high in healthcare, and the revenue from the DTx may not justify the investment. How can pharma build a loyal customer base in a sustainable way as they scale the DTx solution?. 
  • Ways to evolve physician and patient training and education when scaling and growing the product across different geographies and cultures
  • Regulatory landscape and label claims. Regulatory agencies are still in the process of developing universal guidelines for DTx approval and use. Every territory has their rules, how can pharma and DTx companies approach regulations and label claims when scaling across countries?
  • Limited and fragmented reimbursement from public and private payers. Every payer has different needs and populations, how can we address this issue when scaling DTx?
  • Data privacy, security and ownership
* Please note Part 2 of this Sprint will take place on March 22nd

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.